

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](#) on Apr 24, 2025

N-Myc (B8.4.B)

RRID:AB_831602

Type: Antibody

Proper Citation

(Santa Cruz Biotechnology Cat# sc-53993, RRID:AB_831602)

Antibody Information

URL: http://antibodyregistry.org/AB_831602

Proper Citation: (Santa Cruz Biotechnology Cat# sc-53993, RRID:AB_831602)

Target Antigen: N-Myc (B8.4.B)

Host Organism: mouse

Clonality: monoclonal

Comments: validation status unknown check with seller; recommendations: WB, IP; Immunoprecipitation; Western Blot

Antibody Name: N-Myc (B8.4.B)

Description: This monoclonal targets N-Myc (B8.4.B)

Target Organism: mouse, human

Antibody ID: AB_831602

Vendor: Santa Cruz Biotechnology

Catalog Number: sc-53993

Record Creation Time: 20241016T225515+0000

Record Last Update: 20241016T234251+0000

Ratings and Alerts

No rating or validation information has been found for N-Myc (B8.4.B).

No alerts have been found for N-Myc (B8.4.B).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 24 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Abu-Zaid A, et al. (2024) Histone lysine demethylase 4 family proteins maintain the transcriptional program and adrenergic cellular state of MYCN-amplified neuroblastoma. *Cell reports. Medicine*, 5(3), 101468.

Jablonowski CM, et al. (2024) Metabolic reprogramming of cancer cells by JMJD6-mediated pre-mRNA splicing associated with therapeutic response to splicing inhibitor. *eLife*, 12.

Graham MK, et al. (2024) The TERT Promoter is Polycomb-Repressed in Neuroblastoma Cells with Long Telomeres. *Cancer research communications*, 4(6), 1533.

Papadopoulos D, et al. (2024) The MYCN oncoprotein is an RNA-binding accessory factor of the nuclear exosome targeting complex. *Molecular cell*, 84(11), 2070.

Huang M, et al. (2024) ALK upregulates POSTN and WNT signaling to drive neuroblastoma. *Cell reports*, 43(3), 113927.

He T, et al. (2024) Targeting the mSWI/SNF complex in POU2F-POU2AF transcription factor-driven malignancies. *Cancer cell*, 42(8), 1336.

Vidal R, et al. (2024) Association with TFIIC limits MYCN localisation in hubs of active promoters and chromatin accumulation of non-phosphorylated RNA polymerase II. *eLife*, 13.

Atsuta Y, et al. (2024) Direct reprogramming of non-limb fibroblasts to cells with properties of limb progenitors. *Developmental cell*, 59(3), 415.

Jiang H, et al. (2023) Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. *Cancer research*, 83(2), 181.

Tran GB, et al. (2023) Caffeine supplementation and FOXM1 inhibition enhance the antitumor effect of statins in neuroblastoma. *Cancer research*.

Han W, et al. (2022) Targeting HOTAIRM1 ameliorates glioblastoma by disrupting mitochondrial oxidative phosphorylation and serine metabolism. *iScience*, 25(8), 104823.

Das SK, et al. (2022) MYC assembles and stimulates topoisomerases 1 and 2 in a "topoisome". *Molecular cell*, 82(1), 140.

Papadopoulos D, et al. (2022) MYCN recruits the nuclear exosome complex to RNA polymerase II to prevent transcription-replication conflicts. *Molecular cell*, 82(1), 159.

Tao L, et al. (2022) MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastoma. *Nature communications*, 13(1), 3728.

Pearson JD, et al. (2021) Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP/TEAD activity. *Cancer cell*, 39(8), 1115.

D'Oto A, et al. (2021) KDM6B promotes activation of the oncogenic CDK4/6-pRB-E2F pathway by maintaining enhancer activity in MYCN-amplified neuroblastoma. *Nature communications*, 12(1), 7204.

Gao J, et al. (2020) Suppression of ABCE1-Mediated mRNA Translation Limits N-MYC-Driven Cancer Progression. *Cancer research*, 80(17), 3706.

Chung C, et al. (2020) Integrated Metabolic and Epigenomic Reprograming by H3K27M Mutations in Diffuse Intrinsic Pontine Gliomas. *Cancer cell*, 38(3), 334.

Bellamy J, et al. (2020) Increased Efficacy of Histone Methyltransferase G9a Inhibitors Against MYCN-Amplified Neuroblastoma. *Frontiers in oncology*, 10, 818.

Kuchen EE, et al. (2020) Hidden long-range memories of growth and cycle speed correlate cell cycles in lineage trees. *eLife*, 9.